Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709
- PMID: 1424519
- DOI: 10.1016/0732-8893(90)90040-3
Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709
Abstract
The oxazolidinone compound E3709, which contains a 4-pyridyl group, was found to be more active in vitro than other members of this series, such as DuP 721. MIC90 for staphylococci(including methicillin-resistant isolates), streptococci (including Enterococcus faecalis), Clostridia, and diphtheroids was less than 0.5 micrograms/ml. Haemophilus influenzae, Moraxella catarrhalis, and Bacteroides fragilis were less susceptible, with an MIC90 between 2 and 8 micrograms/ml. E3709 MICs of Gram-negative species ranged from 100 to greater than 1000 micrograms/ml. At a concentration of 10 micrograms/ml, E3709 was bactericidal for selected Gram-positive species. A postantibiotic effect of 3 hr was observed against staphylococci. Resistance to E3709 was not detected.
Similar articles
-
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150. Antimicrob Agents Chemother. 1988. PMID: 3348606 Free PMC article.
-
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839. Antimicrob Agents Chemother. 1996. PMID: 8849237 Free PMC article.
-
Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):256-60. doi: 10.1007/BF01965273. Eur J Clin Microbiol Infect Dis. 1989. PMID: 2523807
-
Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.Drugs. 1996;51 Suppl 1:31-7. doi: 10.2165/00003495-199600511-00007. Drugs. 1996. PMID: 8724814 Review.
-
Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin.Clin Infect Dis. 1992 Jun;14 Suppl 2:S189-94; discussion S195-6. doi: 10.1093/clinids/14.supplement_2.s189. Clin Infect Dis. 1992. PMID: 1617037 Review.
Cited by
-
The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin.Antimicrob Agents Chemother. 1997 Oct;41(10):2127-31. doi: 10.1128/AAC.41.10.2127. Antimicrob Agents Chemother. 1997. PMID: 9333036 Free PMC article.
-
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799. Antimicrob Agents Chemother. 1996. PMID: 8851617 Free PMC article.
-
Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.Antimicrob Agents Chemother. 1998 Apr;42(4):947-50. doi: 10.1128/AAC.42.4.947. Antimicrob Agents Chemother. 1998. PMID: 9559817 Free PMC article.
-
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721. Antimicrob Agents Chemother. 1998. PMID: 9517963 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical